ArticleFrontiers in medicine2026
Phenotypic heterogeneity of giant cell arteritis in an Asian cohort: clinical, imaging, and laboratory characteristics.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Giant cell arteritis (GCA) exhibits phenotypic heterogeneity. The diagnosis of large vessel involvement in GCA remains challenging, and conventional inflammatory markers have limitations. This study aimed to characterize phenotypic profiles and explore the role of novel hematological indices in an Asian cohort. Methods: This single-center retrospective study enrolled 110 patients diagnosed with GCA between 2015 and 2025. Patients were classified into cranial (cGCA), mixed (mixGCA), and isolated large-vessel (LV-GCA) phenotypes. Demographics, clinical features, and laboratory parameters-including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and serum albumin-were analyzed. The performance of the 1990 ACR and 2022 ACR/EULAR classification criteria was evaluated. Results: The cohort comprised 110 patients (65 men, 59.1%; 45 women, 40.9%), and was divided into cGCA (44.5%), mixGCA (36.4%), and LV-GCA (19.1%). LV-GCA presented with more constitutional symptoms and limb claudication but fewer cranial symptoms. Novel hematological indices, particularly SII and PLR, showed significant positive correlations with C-reactive protein levels. Multivariate logistic regression analysis revealed that serum albumin level was independently associated with large-vessel involvement (LVI; OR = 0.865, 95% CI [0.767-0.974], Conclusion: GCA presents a distinct clinical profile in this Asian cohort. Novel hematological indices (including SII and PLR) correlate with acute-phase reactants, and serum albumin is associated with LVI. These preliminary findings suggest that these biomarkers, alongside lower-limb arterial ultrasound, may aid in identifying LVI, requiring prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.